Full-Time
Head of Total Rewards
Confirmed live in the last 24 hours
Legend Biotech
1,001-5,000 employees
Develops and commercializes cell therapies
Expert
Somerset County, NJ, USA
You match the following Legend Biotech's candidate preferences
Employers are more likely to interview you if you match these preferences:
- Bachelor Degree Required. Master in HR or related field preferred.
- 10+ year of experience of progressive compensation related development.
- Experience in Pharma industry preferred.
- Certified Compensation Professional (CCP) is a plus.
- Understanding of SEC, SOX, and tax requirements as well as all other government regulations that apply to compensation base and incentive compensation.
- Excellent understanding of U.S. and global compensation and benefits practices.
- Experience with executive and global compensation programs, compensation planning methodologies, and survey/analysis/data collection.
- Lead the total rewards planning & execution, ensure the total rewards strategy is aligned with business objectives.
- Develop and ensure the effectiveness of compensation policies, guidelines and procedures.
- Manage company equity program.
- Establish and evolve compensation programs, such as: grading structure/job family; pay scale and structure; merit planning; short-term incentive plans; equity program; employee engagement programs etc.
- Lead efforts on executive compensation.
- Oversee and assess the services and performance of benefits consultants, brokers, third party administrators and other vendors/providers.
- Oversee management of HRIS system and recommend strategic improvements or system additions to better support the department and organization.
- Identify potential risk and ensure compliance at all levels. Monitor all regulatory compliance requirements (e.g., reporting, disclosure, procedures) for compensation and benefits programs.
- Providing advice to management on compensation and benefits -related topics. Change management and communication related to ongoing or new compensation practices.
- Master in HR or related field preferred.
- Experience in Pharma industry preferred.
- Certified Compensation Professional (CCP) is a plus.
Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their therapies, such as CAR-T, involve modifying a patient's own cells to enhance their ability to fight cancer. Unlike many companies that focus on a single technology, Legend Biotech explores various technologies to find effective treatments. They operate in the personalized medicine sector, discovering, developing, and bringing new therapies to market, generating revenue through licensing and sales. The company emphasizes transparency with investors, regularly updating them on financial results and business developments.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$146.4M
Headquarters
Franklin Township, New Jersey
Founded
2014
Simplify's Take
What believers are saying
- Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.
- New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.
- Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.
What critics are saying
- Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.
- Collaboration with Multiply Labs may face technological challenges, delaying production timelines.
- Financial strain from new R&D facility could affect operational focus if advancements lag.
What makes Legend Biotech unique
- Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
- The company is technology agnostic, exploring multiple platforms for effective cancer treatments.
- Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Sick Leave
Paid Holidays
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -1%Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said
SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr
With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.
SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.
Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).